DOXYCYCLINE - AN OVERVIEW

There have been no clinically considerable variations in the pharmacokinetics of both midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when utilised concomitantly with finerenone. A number of doses of forty mg finerenone after-day by day had no clinically suitable effect on AUC or Cmax of the BCRP and OATP substrate rosuvastatin.This